Tizanidine
Product Images NDC 67296-2102

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-2102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Tizanidine Tablets USP 2 mg, showing a count of 150 tablets. The label states it is Rx Only, is produced by Dr. Reddy's Laboratories Limited, and includes storage and safety warnings. The design features blue and orange text with a barcode and product identifiers.*

FDA Label Image

Container2 (Container2)

Tizanidine Tablets USP 2 mg carton label showing proprietary name, strength, and dosage form. The label states 'Rx Only' and contains 150 tablets. It includes a warning that Tizanidine tablets are not interchangeable with capsules. Manufacturer is Dr. Reddy's Laboratories Limited, with NDC 55111-179-15. The label also provides storage instructions, a barcode, and a note referencing a package insert for prescribing information.*

FDA Label Image

Container3 (Container3)

Tizanidine Tablets, USP 4 mg label for a bottle containing 150 tablets. The label includes strength, quantity, and a warning that tablets are not interchangeable with capsules. It also shows Dr. Reddy's Laboratories Limited as the manufacturer, along with storage and safety information, a barcode, and NDC 55111-180-15.*

FDA Label Image

Container4 (Container4)

Tizanidine Tablets, USP 4 mg bottle label by Dr. Reddy's Laboratories Limited, containing 150 tablets. The label includes dosing information, storage instructions, and a warning that Tizanidine tablets are not interchangeable with capsules. The label also shows the NDC 55111-180-15 and barcode.*

FDA Label Image

Fig1 (Fig1)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) from dosing. It compares four conditions: 2 x 4 mg Tizanidine tablets with food, without food, and 2 x 4 mg Tizanidine capsules with and without food, illustrating the concentration changes within 24 hours post dosing.*

FDA Label Image

Fig2 (Fig2)

A line graph comparing improvement in Ashworth Score over time post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The x-axis shows hours post-dose (0 to 6 hours) and the y-axis shows improvement in Ashworth Score, with error bars for variability.*

FDA Label Image

Fig3 (Fig3)

A chart comparing improvement in Ashworth scores between tizanidine (mean dose 28.8 mg) and placebo groups at three time points: end of titration (study week 3), end of maintenance (study week 7), and endpoint (last observation carried forward). The graph shows mean values with error bars representing variability.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride, showing its fused ring system with chlorine and nitrogen atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.